The Validation of Multifactor Model of Plasma Aβ42 and Total-Tau in Combination With MoCA for Diagnosing Probable Alzheimer Disease

Fubin Jiao,Fang Yi,Yuanyuan Wang,Shouzi Zhang,Yanjun Guo,Wenjin Du,Ya Gao,Jingjing Ren,Haifeng Zhang,Lixin Liu,Haifeng Song,Luning Wang

DOI: https://doi.org/10.3389/fnagi.2020.00212

IF: 4.8

2020-07-21

Frontiers in Aging Neuroscience

Abstract:Alzheimer disease (AD) has an insidious onset and heterogeneous clinical symptoms. The well-accepted biomarkers for clinical diagnosis of AD include β-amyloid (Aβ) deposition and pathologic tau level within cerebral spinal fluid (CSF) and imaging AD pathology such as positive emission tomography (PET) imaging of the amyloid-binding agent Pittsburgh compound B (PET-PiB). However, the high expense and invasive nature of these methods highly limit their wide usage in clinic practice. Therefore, it is imperious to develop less expensive and invasive methods, and plasma biomarkers are the premium targets. In the current study, we utilized a single-blind comparison method; all the probable AD cases met the core clinical National Institute on Aging and Alzheimer's Association (NIA-AA) criteria and validated by PET-PiB. We used ultrasensitive immunomagnetic reduction (IMR) assays to measure plasma Aβ_<i>42</i> and total-tau (t-tau) levels, in combination with different variables including Aβ42 × t-tau value, Montreal Cognitive Assessment (MoCA), and Mini Mental State Examination (MMSE). We used logistic regression to analyze the effect of all these variables in the algorism. Our results showed that (1) plasma Aβ42 and t-tau are efficient biomarkers for AD diagnosis using IMR platform, whereas Aβ42 × t-tau value is more efficient for discriminating control and AD; (2) in the control group, Aβ42 level and age demonstrated strong negative correlation; Aβ42 × t-tau value and age demonstrated significant negative correlation; (3) in the AD group, t-tau level and MMSE score demonstrated strong negative correlation; (4) using the model that Aβ42, Aβ42 × t-tau, and MoCA as the variable to generate receiver operating characteristic (ROC) curve, cutoff value = 0.48, sensitivity = 0.973, specificity = 0.982, area under the curve (AUC) = 0.986, offered better categorical efficacy, sensitivity, specificity, and AUC. The multifactor model of plasma Aβ42 and t-tau in combination with MoCA can be a viable model separate health and AD subjects in clinical practice.

neurosciences,geriatrics & gerontology,gerontology

What problem does this paper attempt to address?

The problem that this paper attempts to solve is to develop a more economical and less invasive method for diagnosing Alzheimer's disease (AD). Currently, the clinical diagnosis of Alzheimer's disease relies on β - amyloid (Aβ) deposition and pathological tau levels in cerebrospinal fluid, as well as methods such as positron emission tomography (PET) imaging. However, these methods are restricted in their wide application in clinical practice due to their high cost and strong invasiveness. Therefore, researchers are committed to finding cheaper and less invasive diagnostic methods, among which blood biomarkers have become the main target.

Specifically, this study uses the ultrasensitive immunomagnetic reduction (IMR) technique to measure the levels of Aβ42 and total tau (t - tau) in plasma, and combines the Montreal Cognitive Assessment (MoCA) and other variables to analyze the influence of these variables on the diagnostic algorithm through logistic regression. The main purpose of the study is to verify whether a multi - factor model using plasma Aβ42 and t - tau in combination with MoCA can effectively distinguish between healthy individuals and patients who may have Alzheimer's disease.

Through this method, the study aims to provide a feasible model for separating healthy people and Alzheimer's disease patients in clinical practice, thereby providing a new approach for the early diagnosis of Alzheimer's disease.